港股異動 | 康希諾生物-B大漲逾15%續創新高 暫四日連升累漲逾57%
格隆匯3月24日丨康希諾生物-B(6185.HK)今日續漲,暫四日連升累漲逾57%,盤中高見127港元再創歷史新高,現報125.3港元,漲15.48%,暫成交1.5億港元,最新總市值279億港元。康希諾生物-B上週三(18日)晨間公佈,由公司與軍事科學院軍事醫學研究院生物工程研究所聯合開發的重組新型冠狀病毒疫苗(腺病毒載體)(Ad5-nCoV)已經通過了臨牀研究註冊審評,獲批進入臨牀試驗。大摩近日發報告稱,將公司目標價由68港元大幅提升至102港元,予“增持”評級,以反映疫苗銷售提升的影響,並密切關注Ad5-nCoV的開發進程,但現階段認為成功率僅為20%左右。該行將公司2020-2022年銷售預測分別升18%、29%及30%,以反映公司市場份額提升,而受惠健康意識提升,旗下疫苗組合的注射情況也有提升,中、長期疫苗產品的貢獻也有增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.